What Researchers Did
Researchers administered a single intraarterial infusion of 2.5 mg/kg bevacizumab after hyperosmotic blood-brain barrier disruption to two pediatric patients with medically intractable radiation necrosis following stereotactic radiosurgery.
What They Found
At a mean follow-up of 8.5 months, both pediatric patients (n=2) experienced significant clinical and radiographic improvement in their radiation necrosis. This targeted intraarterial approach aimed to reduce systemic complications, which are a concern with intravenous bevacizumab.
What This Means for Canadian Patients
This preliminary study suggests that targeted intraarterial anti-VEGF therapy could offer a potential treatment option for Canadian pediatric patients with radiation necrosis that does not respond to conventional medical therapies. If confirmed in larger studies, this approach might provide a way to manage severe radiation necrosis while potentially reducing the systemic side effects associated with intravenous drug administration.
Canadian Relevance
This study has no direct Canadian connection as it was not conducted in Canada, nor did it involve Canadian researchers or patients.
Study Limitations
The primary limitation of this study is its very small sample size, consisting of only two pediatric patients, which prevents generalization of the findings.